Lupus BioTech: The registration clinical study results of MRG003 will be announced at the 2025 ASCO Annual Meeting.

LePu Biotechnology announced that the key pivotal clinical trial results of their self-developed candidate drug MRG003 (used to treat recurrent or metastatic nasopharyngeal carcinoma) will be publicly disclosed in the form of a "blockbuster research abstract" at the 2025 American Society of Clinical Oncology Annual Meeting, and will be presented orally at the meeting. As of June 30, 2024, the objective response rate of the MRG003 group was 30.2%, compared to 11.5% in the chemotherapy group. The progression-free survival of the MRG003 group significantly improved, with a median PFS of 5.8 months. In the mid-term analysis as of December 30, 2024, the median survival periods of the two groups of patients were 17.1 months and 12 months, respectively.